Daiwa Securities Group Inc. raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 1,530.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,983 shares of the biotechnology company’s stock after buying an additional 2,800 shares during the period. Daiwa Securities Group Inc.’s holdings in United Therapeutics were worth $668,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Personalized Indexing Management LLC increased its holdings in shares of United Therapeutics by 0.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 6,419 shares of the biotechnology company’s stock valued at $1,785,000 after purchasing an additional 44 shares in the last quarter. Profund Advisors LLC increased its holdings in shares of United Therapeutics by 0.7% in the fourth quarter. Profund Advisors LLC now owns 6,584 shares of the biotechnology company’s stock valued at $1,831,000 after purchasing an additional 45 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of United Therapeutics by 10.4% in the first quarter. Parallel Advisors LLC now owns 530 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 50 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of United Therapeutics by 6.5% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 899 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 55 shares in the last quarter. Finally, Alaska Permanent Fund Corp increased its holdings in shares of United Therapeutics by 24.6% in the fourth quarter. Alaska Permanent Fund Corp now owns 289 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 95.02% of the company’s stock.
United Therapeutics Trading Up 1.0 %
Shares of NASDAQ UTHR opened at $245.17 on Friday. The company’s fifty day moving average is $224.52 and its 200-day moving average is $232.74. The stock has a market cap of $11.49 billion, a price-to-earnings ratio of 16.51 and a beta of 0.61. United Therapeutics Co. has a twelve month low of $201.65 and a twelve month high of $283.09. The company has a quick ratio of 9.52, a current ratio of 9.84 and a debt-to-equity ratio of 0.16.
Insider Activity at United Therapeutics
In related news, CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $231.40, for a total value of $1,851,200.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,082. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $231.40, for a total value of $1,851,200.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,082. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $209.11, for a total transaction of $1,254,660.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,653,216.89. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,874 shares of company stock valued at $9,036,034. 12.50% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of brokerages recently weighed in on UTHR. UBS Group lowered their price target on shares of United Therapeutics from $330.00 to $310.00 and set a “buy” rating for the company in a report on Monday, April 10th. LADENBURG THALM/SH SH lowered their target price on shares of United Therapeutics from $285.00 to $256.00 in a report on Thursday, May 4th. Morgan Stanley lowered their target price on shares of United Therapeutics from $320.00 to $316.00 and set an “overweight” rating for the company in a report on Monday, April 10th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday. Finally, Argus lowered their target price on shares of United Therapeutics from $300.00 to $280.00 and set a “buy” rating for the company in a report on Friday, April 21st. Two analysts have rated the stock with a sell rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.67.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Five stocks we like better than United Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Can SAIA Continue its Stratospheric Rally?
- How to Evaluate a Stock Before Buying
- Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip
- How Technical Indicators Can Help You Find Oversold Stocks
- 7 Best Industrial REITs to Buy Now
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
